Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of Tuesday, October 6, 2026.
RETURN ON EQUITY (ROE)
N/A
Veraxa Biotech Holding AG
Market Cap
$152.72M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$153.58M
Return on Equity (ROE)
N/A
TTM Avg
13.51%
3Y Avg
15.58%
5Y Avg
15.05%
Market Cap
$153.79M
Return on Equity (ROE)
-170.49%
TTM Avg
-166.01%
3Y Avg
-121.36%
5Y Avg
-104.96%
Market Cap
$151.01M
Return on Equity (ROE)
-155.34%
TTM Avg
-168.75%
3Y Avg
-117.97%
5Y Avg
-104.46%
Market Cap
$149.36M
Return on Equity (ROE)
-59.40%
TTM Avg
-255.06%
3Y Avg
-160.44%
5Y Avg
-112.56%
Market Cap
$156.22M
Return on Equity (ROE)
-14.07%
TTM Avg
-16.23%
3Y Avg
-27.66%
5Y Avg
-19.01%
Market Cap
$148.73M
Return on Equity (ROE)
-131.85%
TTM Avg
-36.69%
3Y Avg
-135.43%
5Y Avg
-129.92%
Market Cap
$148.64M
Return on Equity (ROE)
-69.78%
TTM Avg
-41.37%
3Y Avg
-26.34%
5Y Avg
-26.08%
Market Cap
$148.27M
Return on Equity (ROE)
-21.38%
TTM Avg
-42.33%
3Y Avg
-37.95%
5Y Avg
-45.57%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Veraxa Biotech Holding AG (VRXA) | $152.72M | N/A | N/A | N/A | N/A |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $153.58M | N/A | 13.51% | 15.58% | 15.05% |
| Neuronetics, Inc. (STIM)vs › | $153.79M | -170.49% | -166.01% | -121.36% | -104.96% |
| Cardiol Therapeutics Inc. (CRDL)vs › | $151.01M | -155.34% | -168.75% | -117.97% | -104.46% |
| ALX Oncology Holdings Inc. (ALXO)vs › | $149.36M | -59.40% | -255.06% | -160.44% | -112.56% |
| Inogen, Inc. (INGN)vs › | $156.22M | -14.07% | -16.23% | -27.66% | -19.01% |
| Korsana Biosciences, Inc. (KRSA)vs › | $148.73M | -131.85% | -36.69% | -135.43% | -129.92% |
| Voyager Therapeutics, Inc. (VYGR)vs › | $148.64M | -69.78% | -41.37% | -26.34% | -26.08% |
| Anavex Life Sciences Corp. (AVXL)vs › | $148.27M | -21.38% | -42.33% | -37.95% | -45.57% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $146.62M | -183.44% | -114.28% | -67.72% | -46.03% |
ROE
N/A
ROA
N/A
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
